The U.S. Food and Drug Administration has approved Siliq (brodalumab) as a treatment for adults with moderate-to-severe plaque psoriasis.
Siliq is administered as an injection.
The drug was created for those who are candidates for systemic therapy, a process that involves treatments using substances that travel through the blood stream, or phototherapy, a process that involves ultraviolet light treatment. If these patients have failed to respond or stopped responding to other systemic therapies, they can now try Siliq.
"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today's approval provides patients with another treatment option for their psoriasis," Dr. Julie Beitz, director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in a statement. "Patients and their health care providers should discuss the benefits and risks of Siliq before considering treatment."
Psoriasis, an autoimmune disorder, is a skin condition causing patches of skin redness and flaking. It occurs most often in people between the ages of 15 and 35, more commonly in patients with a family history of the disease.
Siliq will include a label boxed warning about the observed risk of suicidal ideation and behavior that was seen in clinical trials.
Alerts Sign-up